Catalyst Wire Dossier Catalyst Wire Dossier
EMA approval · 2026-08-27

EMA Authorised: Bilprevda (denosumab) — Sciencepharma Sp. z o.o

View source ↗

Summary

Authorised new medicine Bilprevda (denosumab) by Sciencepharma Sp. z o.o. for Giant Cell Tumor of Bone and bone neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BILPREVDA (DENOSUMAB)

Snippet

Status: Authorised. Therapeutic area: Giant Cell Tumor of Bone;Neoplasms, Bone Tissue. MAH: Sciencepharma Sp. z o.o. Decision date: 13/07/2026